JPMorgan Chase & Co. Cuts Teladoc Health (NYSE:TDOC) Price Target to $9.00

Teladoc Health (NYSE:TDOC - Free Report) had its target price decreased by JPMorgan Chase & Co. from $16.00 to $9.00 in a research report report published on Monday morning, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the health services provider's stock.

Other equities research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft reduced their price objective on Teladoc Health from $15.00 to $10.00 and set a hold rating on the stock in a research report on Friday, August 2nd. Piper Sandler reduced their price target on Teladoc Health from $25.00 to $10.00 and set an overweight rating on the stock in a report on Tuesday, August 6th. Canaccord Genuity Group lowered their price objective on Teladoc Health from $25.00 to $17.00 and set a buy rating for the company in a research note on Thursday, August 1st. Evercore ISI cut their target price on shares of Teladoc Health from $14.00 to $10.00 and set an in-line rating on the stock in a research report on Tuesday, July 9th. Finally, Truist Financial decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a hold rating for the company in a research report on Friday, August 2nd. Fourteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Teladoc Health presently has a consensus rating of Hold and a consensus price target of $12.44.

Teladoc Health Price Performance

Shares of TDOC stock traded down $0.11 on Monday, hitting $7.31. 3,752,266 shares of the company's stock were exchanged, compared to its average volume of 5,489,097. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The stock has a market cap of $1.25 billion, a P/E ratio of -5.18 and a beta of 0.93. Teladoc Health has a 12 month low of $6.77 and a 12 month high of $23.19. The company has a 50 day moving average of $8.79 and a 200 day moving average of $12.25.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The business had revenue of $642.44 million during the quarter, compared to analysts' expectations of $649.34 million. On average, equities research analysts predict that Teladoc Health will post -0.7 EPS for the current year.

Insider Activity

In related news, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the transaction, the chief marketing officer now directly owns 45,158 shares of the company's stock, valued at $343,200.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CMO Stephany Verstraete sold 15,000 shares of the business's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the sale, the chief marketing officer now directly owns 45,158 shares of the company's stock, valued at approximately $343,200.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vidya Raman-Tangella sold 3,857 shares of the company's stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the transaction, the insider now directly owns 33,667 shares in the company, valued at $274,049.38. The disclosure for this sale can be found here. Insiders sold 42,880 shares of company stock worth $355,689 in the last quarter. 0.95% of the stock is owned by corporate insiders.

Institutional Trading of Teladoc Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP bought a new stake in Teladoc Health during the 2nd quarter worth approximately $45,267,000. Point72 Asset Management L.P. boosted its position in shares of Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider's stock valued at $51,865,000 after buying an additional 3,655,436 shares during the last quarter. Clearline Capital LP boosted its position in shares of Teladoc Health by 395.6% during the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider's stock valued at $42,682,000 after buying an additional 3,483,665 shares during the last quarter. Vanguard Group Inc. grew its holdings in Teladoc Health by 11.8% during the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider's stock worth $377,451,000 after buying an additional 1,855,480 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Teladoc Health by 25.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider's stock valued at $82,636,000 after buying an additional 767,999 shares during the last quarter. Institutional investors own 76.82% of the company's stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.